Second, the CROWN trial is the only randomized phase III trial that has directly compared lorlatinib and crizotinib for patients with advanced ALK+ NSCLC, and many input parameters (OS, PFS, AEs, etc.)in our model were obtained from this trial. Here, ALK is linked to non-small cell lung carcinoma.